Zeria Pharmaceutical (4559) Fundamentals 2026 — P/E 11.0x, Revenue Analysis | SniperIQ
Zeria Pharmaceutical (4559) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥92.9B, trading at ¥2108.00 on the JPX. This SniperIQ fundamentals page covers Zeria Pharmaceutical's valuation (P/E 11.0x, P/B 0.9x), profitability (net margin 9.5%), revenue (¥89.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zeria Pharmaceutical's market cap?
Zeria Pharmaceutical (4559) has a market capitalization of approximately ¥92.9B, trading at ¥2108.00 on the JPX. Market cap moves with the live share price.
What is Zeria Pharmaceutical's P/E ratio?
Zeria Pharmaceutical's trailing twelve-month P/E ratio is 11.0x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zeria Pharmaceutical?
Zeria Pharmaceutical runs a net profit margin of 9.5%, a gross margin of 73.1%, and an operating margin of 13.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zeria Pharmaceutical generate?
Zeria Pharmaceutical reported revenue of ¥89.2B for fiscal year 2025, with net income of ¥8.5B and earnings per share (EPS) of 191.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zeria Pharmaceutical pay a dividend?
Zeria Pharmaceutical offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zeria Pharmaceutical financially healthy?
Zeria Pharmaceutical carries a debt-to-equity ratio of 0.36x and a current ratio of 1.48x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zeria Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zeria Pharmaceutical (4559) the key facts are: market cap ¥92.9B, P/E 11.0x, revenue ¥89.2B, 52-week range 1878-2434. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zeria Pharmaceutical's full fundamentals live
Get Zeria Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.